Keyword: David Hung

David Hung, M.D. is getting back into cancer with his new oncology startup.

After a very brief and tumultuous tenure at startup Axovant with big hopes and backing, former Medivation chief David Hung, M.D., has resigned as CEO.

David Hung's decision to join Axovant after selling Medivation to Pfizer for $14 billion now looks more like a gamble that isn't paying off.

Axovant’s run of bad news shows no signs of letting up, with negative results in a phase 2b trial spelling the end for lead candidate intepirdine.

Axovant becomes the latest company to see a major miss in Alzheimer's.

Medivation founder David Hung has become CEO of Axovant, Destiny Pharma tapped Neil Clark as CEO and Allergan hired a finance expert.

Axovant Sciences is capitalizing on the attention it has received from welcoming biotech icon David Hung as its new CEO with a $125 million share offering.

Axovant Sciences has appointed Medivation founder David Hung, M.D., as CEO.

Move over Sanofi, your original $9.3 billion bid and even your second, sweetened offer has been blown out of the water by the $14 billion being put on the table by Pfizer--and Medivation’s CEO David Hung has decided that's his best bet and has taken the deal.